Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02107092




Registration number
NCT02107092
Ethics application status
Date submitted
3/04/2014
Date registered
8/04/2014
Date last updated
15/08/2018

Titles & IDs
Public title
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Scientific title
Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]
Secondary ID [1] 0 0
ZS-004E
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hyperkalemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sodium Zirconium Cyclosilicate

Experimental: Sodium Zirconium Cyclosilicate - Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.


Treatment: Drugs: Sodium Zirconium Cyclosilicate
Oral 10g once daily with breakfast for 11 months.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of Subjects With Average Serum Potassium Values = 5.1 mmol/L
Timepoint [1] 0 0
11 months
Secondary outcome [1] 0 0
Proportion of Subjects With Average Serum Potassium Values = 5.5 mmol/L
Timepoint [1] 0 0
11 months

Eligibility
Key inclusion criteria
- Provision of written informed consent.

- Completed the ZS-004 DBRMP Study Day 29 visit or discontinued study ZS-004 during the
DBRMP due to hypo- or hyperkalemia and able to start dosing in ZS-004E within two (2)
days after the last dose of Investigational product in ZS-004.

- Subject must have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive at the
ZS-004 DBRMP Study Day 29 visit or a mean i-STAT potassium value from two consecutive
measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase Day 1 that is
3.5 to 6.2 mmol/l inclusive if the subject discontinued study ZS-004 during the DBRMP
due to hypo- or hyperkalemia .
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed
blood specimen, history of severe leukocytosis or thrombocytosis.

- Subjects who received alternative treatment for hyperkalemia while participating in
study ZS-004.

- Subjects with a life expectancy of less than 3 months.

- Subjects who are severely physically or mentally incapacitated and who in the opinion
of investigator are unable to perform the subjects' tasks associated with the
protocol.

- Women who are pregnant, lactating, or planning to become pregnant.

- Subjects with diabetic ketoacidosis.

- Presence of any condition which, in the opinion of the investigator, places the
subject at undue risk or potentially jeopardizes the quality of the data to be
generated.

- Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

- Treatment with a drug or device other than ZS within the last 30 days that has not
received regulatory approval at the time of study entry.

- Subjects with cardiac arrhythmias that require immediate treatment.

- Subjects on dialysis.

Study design
Purpose of the study
Supportive Care
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/05/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/08/2015
Sample size
Target
Accrual to date
Final
123
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Gosford
Recruitment hospital [2] 0 0
- Woolloongabba
Recruitment hospital [3] 0 0
- Heidelberg
Recruitment hospital [4] 0 0
- Melbourne
Recruitment hospital [5] 0 0
- Parkville
Recruitment postcode(s) [1] 0 0
- Gosford
Recruitment postcode(s) [2] 0 0
- Woolloongabba
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment postcode(s) [4] 0 0
- Melbourne
Recruitment postcode(s) [5] 0 0
- Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maine
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
South Africa
State/province [18] 0 0
Meyerspark
Country [19] 0 0
South Africa
State/province [19] 0 0
Port Elizabeth
Country [20] 0 0
South Africa
State/province [20] 0 0
Somerset West

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ZS Pharma, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29
visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l
inclusive or who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and
have a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on
Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the
option to participate in ZS-004E (NCT 021070920). Subjects who discontinued from study ZS-004
due to any other reasons (e.g. adverse events, poor compliance, investigator decision) will
not be entered into study ZS-004E. All subjects who continue into the extension study must
begin dosing within two (2) days after the last dose of investigational product in ZS-004.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02107092
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Henrik Rasmussen, MD, PhD
Address 0 0
ZS Pharma, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02107092